ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2020
Risk stratification based on J-ACCESS risk models with myocardial perfusion imaging: Risk versus outcomes of patients with chronic kidney disease.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association between an Early Revascularization Strategy and Major Cardiac Events Based on Left Ventricular Dyssynchrony in Patients at Intermediate Risk of Major Cardiac Events Using the J-ACCESS Risk Model.Internal medicine (Tokyo, Japan) · 2024Article
- External validation and update of the J-ACCESS model in an Italian cohort of patients undergoing stress myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- J-ACCESS investigation and nuclear cardiology in Japan: implications for heart failure.Annals of nuclear medicine · 2023Review
- Seeing is believing: Visualization of multivariable risk models.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Prediction of Cancer-Specific Survival of Brainstem Glioma in Children Based on Risk Stratification Model.Computational and mathematical methods in medicine · 2022Article
- Cardiovascular event risk estimated after coronary revascularization and optimal medical therapy: J-ACCESS4 prognostic study.Annals of nuclear medicine · 2021Article
- Cardiovascular risk prediction models with myocardial perfusion imaging in chronic kidney disease: ACCESSing digits or focusing on the patient?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to validate the accuracy of major-event risk models created in the multicenter J-ACCESS prognostic study in a new cohort of patients with chronic kidney disease (CKD). METHODS AND
resultsThree multivariable J-ACCESS risk models were created to predict major cardiac events (cardiac death, non-fatal acute coronary syndrome, and severe heart failure requiring hospitalization): Model 1, four variables of age, summed stress score, left ventricular ejection fraction and diabetes; Model 2 with five variables including estimated glomerular filtration rate (eGFR, continuous); and Model 3 with categorical eGFR. The validation data used three-year (3y) cohort of patients with CKD (n = 526, major events 11.2%). Survival analysis of low (< 3%/3y), intermediate (3% to 9%/3y), and high (> 9%/3y)-risk groups showed good stratification by all three models (actual event rates: 3.1%, 9.9%, and 15.9% in the three groups with eGFR ≥ 15 mL/min/1.73 m
conclusionThe J-ACCESS risk models can stratify patients with CKD and eGFR ≥ 15 mL/min/1.73 m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.